Patel Sanj K

Patel Sanj K, chairman and CEO of Kiniksa Pharmaceuticals (KNSA), has been a consistent seller of company stock over the past two months, with Form 4 filings showing no open-market purchases during the period. The most recent cluster of transactions occurred between April 28 and May 1, 2026, when Patel executed eight open-market sales totaling roughly $28.6 million. The largest single-day disposition came on April 28, with four separate sales aggregating approximately $25 million, including one block worth $12.67 million. Smaller sales followed on April 29 ($1.22 million), April 30 ($115,635), and May 1 ($2.62 million). The sales were paired with option exercises on the same dates, a mechanical pattern in which Patel converted vested options into shares and immediately sold them. The exercise values—$4.47 million on April 28, $697,285 on April 29, $66,221 on April 30, and $1.5 million on May 1—roughly offset the sale proceeds, indicating the transactions were designed to monetize existing holdings rather than acquire new shares. Notably, Patel reported zero acquisitions (no open-market buys, no grants, no gifts) across all 42 filings in the dataset, reinforcing a purely dispositional stance. Across the entire filing history, Patel has sold $39.4 million worth of KNSA stock with no corresponding buys, a ratio that signals strong bearish sentiment from the company's top executive. The recent activity also includes a tax-withholding transaction (code F) on April 7 valued at $236,429, which is an automatic consequence of equity vesting rather than a discretionary trade. While the pattern is unambiguous in its selling bias, the filings do not indicate whether these sales reflect portfolio diversification, personal liquidity needs, or a view on the company's valuation—factors that are not disclosed in Form 4 data.